AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Go back to AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis| AbbVie (NYSE: ABBV) | Delayed: 255.99 +2.69 (1.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $253.30 | 52 Week High | $68.12 | |||
| Open | $253.98 | 52 Week Low | $50.71 | |||
| Day High | $258.38 | P/E | 55.53 | |||
| Day Low | $253.10 | EPS | $4.61 | |||
| Volume | 1,987,582 | |||||
